Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB06674_nanopub.RAto555AS89SSO-NqyfzLbW2H-dU-Ohn5OmuwD9CQmjAQ#assertion>. }
Showing items 1 to 18 of
18
with 100 items per page.
- drugbank:DB06674 type drugbank_vocabulary:Drug assertion.
- drugbank:DB06674 label "golimumab [drugbank:DB06674]" assertion.
- drugbank:DB06674 seeAlso DB06674 assertion.
- drugbank:DB06674 seeAlso golimumab.html assertion.
- drugbank:DB06674 seeAlso simponi-drug.htm assertion.
- drugbank:DB06674 identifier "drugbank:DB06674" assertion.
- drugbank:DB06674 description "Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed." assertion.
- drugbank:DB06674 title "golimumab" assertion.
- drugbank:DB06674 bio2rdf_vocabulary:identifier "DB06674" assertion.
- drugbank:DB06674 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB06674 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB06674" assertion.
- drugbank:DB06674 bio2rdf_vocabulary:x-identifiers.org DB06674 assertion.
- drugbank:DB06674 drugbank_vocabulary:drugbank-id "DB06674" assertion.
- drugbank:DB06674 drugbank_vocabulary:x-cas cas:476181-74-5 assertion.
- drugbank:DB06674 drugbank_vocabulary:x-atc atc:L04AB06 assertion.
- drugbank:DB06674 drugbank_vocabulary:x-kegg kegg:D04358 assertion.
- drugbank:DB06674 drugbank_vocabulary:x-wikipedia wikipedia:Golimumab assertion.
- drugbank:DB06674 drugbank_vocabulary:x-ndc ndc:57894-071-01 assertion.